top of page

Nasdaq-listed SeqLL prices $1.8 million offering

SeqLL provides life sciences instrumentation and research services

SeqLL Inc. (NASDAQ: SQL and SQLLW) ("SeqLL" or the "Company"), a technology company providing life sciences instrumentation and research services, today announced that it has entered into a securities purchase agreement (the "Agreement") with institutional investors to purchase 2,000,000 of its shares of common stock at a purchase price of $0.90 per share of common stock in a registered direct offering (the "Offering"). The gross proceeds to the Company from the Offering are estimated to be approximately $1.8 million before deducting the placement agent’s fees and other Offering expenses.

Maxim Group LLC is acting as the sole placement agent in connection with the Offering. The Offering is expected to close on or about February 15, 2023, subject to the satisfaction of customary closing conditions.

The securities described above are being offered pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-268319), which was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on December 8, 2022. The Offering will be made only by means of a prospectus supplement that forms a part of such registration statement. A prospectus supplement relating to the securities will be filed by the Company with the SEC. When available, copies of the prospectus supplement relating to the Offering, together with the accompanying prospectus, can be obtained at the SEC's website at or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at or telephone at (212) 895-3745.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Source: Maxim Group LLC


If your company has business or financial objectives check out:

Advisory services provided by FC Global Strategies

Medical and Pharma Insider’s AI Connect Marketing Program

To have your news published and distributed by Medical and Pharma Insider, go to BCI News Service.

Check out Medical and Pharma Insider for the latest industry news.


Los comentarios se han desactivado.
bottom of page